Hunan Warrant Pharmaceutical Co.,Ltd

Equities

688799

CNE100004P73

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-13 pm EDT 5-day change 1st Jan Change
44.39 CNY +0.66% Intraday chart for Hunan Warrant Pharmaceutical Co.,Ltd -1.49% -9.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Warrant Pharmaceutical's Diclofenac Tablets Passes Regulatory Evaluation MT
Hunan Warrant Pharma Passes GMP Compliance Inspection MT
Warrant Pharmaceutical's Heart Disease Medication Passes Generic Drug Evaluation in China MT
Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Warrant Pharmaceutical Gets Nod to Market Clopidogrel Bisulfate MT
Zhuhai Qianlie Pharmaceutical Co., Ltd. announced that it expects to receive CNY 25 million in funding from Hunan Warrant Pharmaceutical Co.,Ltd CI
Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Warrant Pharma Unit Registers Arthritis Drug in South Korea MT
Warrant Pharma Secures Product Registration Certificate in South Korea MT
Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Warrant Pharma Gets Regulatory Green Light to Issue Bonds MT
Warrant Pharma Gets Registration Certificate in China for Asthma Drug MT
Hunan Warrant Pharma Posts 12.2% Rise in 2022 Profit MT
Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hunan Warrant Pharma's Drug Production Base Passes Regulator's GMP Inspection MT
Hunan Warrant Pharma’s Hepatitis Drug Included in China’s Medical Insurance Catalog MT
Hunan Warrant Pharma to Raise 691 Million Yuan For New Production Base MT
Hunan Warrant Pharmaceutical Gets Regulatory Nod for Anemia Drug in China MT
Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Warrant Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Warrant Pharmaceutical Co.,Ltd(SHSE:688799) added to Shanghai Stock Exchange A Share Index CI
Hunan Warrant Pharmaceutical Co.,Ltd(SHSE:688799) added to Shanghai Stock Exchange Composite Index CI
Hunan Warrant Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Hunan Warrant Pharmaceutical Co.,Ltd
More charts
Hunan Warrant Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw materials, chemical pharmaceutical preparations and traditional Chinese medicine preparations. The Company's products include pharmaceutical preparations, raw materials and intermediates, plant extracts and food. Its products cover areas such as digestion, breathing, and anti-infection. The Company mainly conducts business within the domestic market.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
44.39 CNY
Average target price
59 CNY
Spread / Average Target
+32.91%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688799 Stock
  4. News Hunan Warrant Pharmaceutical Co.,Ltd
  5. Warrant Pharmaceutical's Heart Disease Medication Passes Generic Drug Evaluation in China
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW